A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Copyright © 2021 Elsevier Inc. All rights reserved..
INTRODUCTION: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML.
MATERIALS AND METHODS: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML.
RESULTS: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported.
CONCLUSION: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 21(2021), 8 vom: 28. Aug., Seite e686-e692 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gemici, Aliihsan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Completed 28.01.2022 Date Revised 28.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2021.04.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32608097X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32608097X | ||
| 003 | DE-627 | ||
| 005 | 20231225193821.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2021.04.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM32608097X | ||
| 035 | |a (NLM)34059487 | ||
| 035 | |a (PII)S2152-2650(21)00147-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gemici, Aliihsan |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2022 | ||
| 500 | |a Date Revised 28.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML | ||
| 520 | |a MATERIALS AND METHODS: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML | ||
| 520 | |a RESULTS: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported | ||
| 520 | |a CONCLUSION: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a Bcl2 | |
| 650 | 4 | |a Inhibitor | |
| 650 | 4 | |a Real life | |
| 650 | 4 | |a Venetoclax | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 700 | 1 | |a Ozkalemkas, Fahir |e verfasserin |4 aut | |
| 700 | 1 | |a Dogu, Mehmet Hilmi |e verfasserin |4 aut | |
| 700 | 1 | |a Tekinalp, Atakan |e verfasserin |4 aut | |
| 700 | 1 | |a Alacacioglu, Inci |e verfasserin |4 aut | |
| 700 | 1 | |a Guney, Tekin |e verfasserin |4 aut | |
| 700 | 1 | |a Ince, Idris |e verfasserin |4 aut | |
| 700 | 1 | |a Geduk, Ayfer |e verfasserin |4 aut | |
| 700 | 1 | |a Cagliyan, Gulsum Akgun |e verfasserin |4 aut | |
| 700 | 1 | |a Maral, Senem |e verfasserin |4 aut | |
| 700 | 1 | |a Serin, Istemi |e verfasserin |4 aut | |
| 700 | 1 | |a Gunduz, Eren |e verfasserin |4 aut | |
| 700 | 1 | |a Karakus, Volkan |e verfasserin |4 aut | |
| 700 | 1 | |a Bekoz, Huseyin Saffet |e verfasserin |4 aut | |
| 700 | 1 | |a Eren, Rafet |e verfasserin |4 aut | |
| 700 | 1 | |a Pinar, Ibrahim Ethem |e verfasserin |4 aut | |
| 700 | 1 | |a Gunes, Ahmet Kursad |e verfasserin |4 aut | |
| 700 | 1 | |a Sargın, Fatma Deniz |e verfasserin |4 aut | |
| 700 | 1 | |a Sevindik, Omur Gokmen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 21(2021), 8 vom: 28. Aug., Seite e686-e692 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:8 |g day:28 |g month:08 |g pages:e686-e692 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2021.04.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 8 |b 28 |c 08 |h e686-e692 | ||